## **Post-Braidwood Comparison of USPSTF Recommendations**



On Thursday, March 30, 2023, Judge O'Connor released a final opinion on remedies in <u>Braidwood Management vs.</u> <u>Becerra</u>, a case regarding the constitutionality of the ACA's coverage of United States Preventive Services Task Force (USPSTF) recommended preventive services. The ACA added section 2713 to the Public Health Service Act ("Section 2713") which requires, among other things, that certain plans cover USPSTF A and B recommended services with no cost-sharing. In his final opinion, Judge O'Connor ruled that plans would only be required to cover USPSTF A and B recommended services with no cost-sharing that were in effect prior to March 23, 2010 (the date of enactment of the ACA).

The Judge's ruling has a direct impact on what preventive services would be covered with no cost-sharing. There is concern that requiring plans to cover preventive services that existed as of March 23, 2010, discount the latest evidence around effective cancer prevention and early detection. The following chart compares the current USPSTF recommendations to those that were in place as of March 23, 2010, showing the differences in the recommendations that would be impacted by the ruling.<sup>2</sup>

Research has consistently shown the benefits of providing coverage of preventive services at no cost to individuals. ACS CAN is disappointed in the March 30<sup>th</sup> ruling in the <u>Braidwood</u> case, which threatens to erode more than a decade of progress reducing cancer deaths and suffering. ACS CAN will continue to closely monitor the ongoing litigation and will continue to support and advocate for coverage of evidence-based preventive services at no cost sharing.

## **Cancer Screenings**

USPSTF Recommendation	Who is Covered	What is Covered	Key Difference Between Recommendations
		Cervical Cancer <sup>3,4,5</sup>	
August 21, 2018*	("A")	with Pap alone;  Women Aged 30-65 every 3 years with Pap alone; every 5 years with high-risk human papillomavirus (hrHPV) testing alone; or every 5 years with hrHPV testing in	The 2018 recommendation specifies that screening begin at age 21; excluding teens (who were included in the 2003 recommendation). It adds the option for HPV testing and cotesting (neither of which were included in the 2003 recommendation) and provides additional information on specific tests to be covered; interval of testing
	Women up to age 65	Recommends starting screening at	depends on the modality of test (up to 5 years).

<sup>&</sup>lt;sup>1</sup> The case also challenged recommendations made by the Advisory Committee on Vaccine Practices (ACIP) and the Health Resources and Services Administration (HRSA), but the judge ruled in the government's favor on those claims, so this reference is limited to USPSTF recommendations. Both plaintiffs and the government are appealing the decision to the US Court of Appeals for the Fifth Circuit. See <u>Braidwood Management Inc. v Becerra, (4:20-cv-00283), District Court, N.D. Texas.</u>

<sup>&</sup>lt;sup>2</sup> Note that some of the pre 2010 USPSTF recommendations are written to explain the risks and benefits and are not as clear recommendation statements as newer recommendations. Therefore, some of the differences may not be clear or subject to interpretation.

<sup>&</sup>lt;sup>3</sup> Section 2713 also requires health plans to cover recommendations from ACIP and the HRSA (including those for well-women care). HRSA also recommends cervical cancer screening recommendations. Thus, it is possible that some women may still have access to cervical cancer screening as a result of the HRSA guidelines, which were left intact by the district court's decision.

<sup>&</sup>lt;sup>4</sup> The USPSTF issued cervical cancer screening recommendation in March 2012.

<sup>&</sup>lt;sup>5</sup> The USPSTF is currently in the process of updating its cervical cancer screening recommendations.

USPSTF			Key Difference Between
Recommendation	Who is Covered	What is Covered	Recommendations
	· ·	(whichever is first) at least every 3 years with cervical cytology	
		Colorectal Cancer <sup>6</sup>	
May 18, 2021  October 15, 2008	Adults Aged 45-49 ("B")  Adults Aged 50 to 75	year) (stool based)  FIT (every year) (stool based)  SDNA-FIT (every 1-3 years) (stool based)  Colonoscopy (every 10 years)  CT colonography (every 5 years)  Flexible sigmoidoscopy (every 5 years)  Flexible sigmoidoscopy with FIT (flex sig over 10 years plus FIT every year)  Clarification that follow-on colonoscopies are part of the screening continuum.	The 2021 recommendation lowers the minimum age of screening to 45 (consistent with the 2018 American Cancer Society guidelines). Additional testing modalities are included in the recommendation, including the FIT and sDNA-FIT tests (e.g., Cologuard) that were not included and/or yet developed in 2008.  Also, 2021 recommendation clarified that follow-on colonoscopies are part of the screening continuum, which the Tri-Agencies clarified should be provided at no cost-sharing. <sup>7</sup>
Lung Cancer <sup>8</sup>			
March 9, 2021	Adults aged 50 to 80 with a 20 pack-year history and currently smoke or have quit within the past 15 years ("B")	for lung cancer with low-dose computed tomography (LDCT)  Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that	<b>NEW RECOMMENDATION</b> :  The pre-ACA USPSTF recommendation did not recommend lung cancer screening.

<sup>&</sup>lt;sup>6</sup> The USPSTF issued colorectal cancer screening recommendations in <u>June 2016</u>.

<sup>&</sup>lt;sup>7</sup> FAQ about Affordable Care Act Implementation Part 51, Families First Coronavirus Response Act and Coronavirus Aid, Relief, and Economic Security Act Implementation (Jan. 10, 2022), available at <a href="https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-51.pdf">https://www.dol.gov/sites/dolgov/files/EBSA/about-ebsa/our-activities/resource-center/faqs/aca-part-51.pdf</a>.

<sup>&</sup>lt;sup>8</sup> The USPSTF issued lung cancer screening recommendations in <u>December 2013</u>.

USPSTF			Key Difference Between
Recommendation	Who is Covered	What is Covered	Recommendations
May 15, 2004	Asymptomatic Adults ("I")	USPSTF concludes that the evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low dose computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests.	
		Breast Cancer Screening <sup>9</sup>	
January 11, 2016*	T	Women Aged 50-74 biennial screening mammography	
<u>December 15, 2009</u>	· ·	women Aged 50-74 bienniai	Due to subsequent Congressional action, plans are required to cover the more inclusive Sept 2002 USPSTF recommendation so this
September 3, 2002	("B")	mammography, with or without clinical breast examination (CBE), every 1-2 years	recommendation is not impacted by the decision.
	Skin Ca	ncer Prevention: Behavioral Counse	ling <sup>10</sup> , 11
March 20, 2018	adolescents, children, and parents of young children, ages 6	to reduce their risk of skin cancer	NEW RECOMMENDATION:  The pre-ACA USPSTF recommendation received an "I" rating and thus plans were not required to cover skin cancer
October 6, 2003	All Persons ("I")	USPSTF concludes that the evidence is insufficient to recommend for or against routine counseling by primary care clinicians to prevent skin cancer.	behavioral counseling.
Breasts Cancer – Medication to Reduce Risk <sup>12</sup>			
September 3, 2019	risk for breast cancer	prescribe risk-reducing	The 2002 recommendation recommends a discussion and the use as tools such as the Gail Model <sup>13</sup> to "help individual

<sup>&</sup>lt;sup>9</sup> The USPSTF is currently <u>in the process</u> of updating its breast cancer screening recommendations.

<sup>&</sup>lt;sup>10</sup> The USPSTF issued skin cancer prevention recommendations in May 2012.

<sup>&</sup>lt;sup>11</sup> The USPSTF is currently in the process of updating its skin cancer screening recommendations.

<sup>&</sup>lt;sup>12</sup> The USPSTF issued breast cancer medication to reduce risk recommendations in <u>September 2013</u>.

<sup>&</sup>lt;sup>13</sup> Of note, the Gail model was developed specifically for White women.

USPSTF	Who is Covered	What is Covered	Key Difference Between
Recommendation	vviio is covered	What is covered	Recommendations
	("B")	to women who are at increased risk for breast cancer and at low risk for	patients considering tamoxifen therapy estimate the potential benefit" and did not specify an age and references high versus increased risk.
July 8, 2002		chemoprevention with women at high risk for breast cancer and at	The 2019 recommendation includes raxloxifene, aromatase inhibitors, and tamoxifen. The 2002 recommendation included tamoxifen.
E	RCA-Related Cancer:	Risk Assessment, Genetic Counselir	ng & Genetic Testing <sup>15</sup>
August 20, 2019	Women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with BRCA1/2 gene mutation ("B")	<ul> <li>Recommends primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appropriate brief familial risk assessment tool.</li> <li>Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.</li> </ul>	The 2005 recommendation was only for women had a family history associated with increased risk, and primary care providers referred them to genetic counseling without further assessment. The 2019 recommendation extended the recommendation to also include women who are cancer free, breast, ovarian, tubal and peritoneal cancer survivors. The 2019 recommendation also provides stronger language about ancestry that applies predominantly to Ashkenazi Jews related to risk. The 2019 recommendation advises primary care providers to use an assessment tool to determine who should be referred to genetic counseling. 16
<u>September 15,</u> <u>2005</u>	Women, at Increased Risk ("B")	Recommends women whose family history is associated with an increased risk for deleterious mutations in <i>BRCA1</i> or <i>BRCA2</i> genes be referred for genetic counseling and evaluation for <i>BRCA</i> testing	

<sup>1/</sup> 

<sup>&</sup>lt;sup>14</sup> Of note, in the 2002 Clinical Considerations section of the Recommendation and Rational, the USPSTF states that there is less evidence evaluating raloxifene for chemoprevention, that trials are ongoing, and there was reason to believe that its benefit profile would be similar to tamoxifen.

<sup>&</sup>lt;sup>15</sup> The USPSTF issued BRCA-related cancer recommendations in <u>December 2013</u>.

<sup>&</sup>lt;sup>16</sup> This recommendation was one of the first to address transgendered individuals (in this case trans men). The 2019 recommendation specifically notes: "While this recommendation applies for women, the net benefit estimates are driven by biological sex (i.e., male/female) rather than gender identity. Persons should consider their sex at birth to determine which recommendation best applies to them." A similar statement was not included in the 2005 recommendation.

## **Behavioral Risk Factors**

USPSTF	Who is covered	What is covered	Key Difference Between
Recommendation	wno is covered	what is covered	Recommendations
Hea	Ithy Weight <sup>17</sup> and We	eight Gain in Pregnancy: Behavioral	Counseling Interventions
May 25, 2021	Pregnant persons ("B")	Recommends that clinicians offer pregnant persons effective	
		behavioral counseling interventions aimed at promoting healthy weight	NEW RECOMMENDATION:
		gain and preventing excess	There was no pre-ACA USPSTF
		gestational weight gain in	recommendation.
		pregnancy.	
There have not beer	any other historical	recommendations.	
Weight Loss to Prev	ent Obesity-Related	Morbidity and Mortality in Adults: B	Sehavioral Interventions
September 18,	Adults	Recommends that clinicians offer	
<u>2018</u>	("B")	or refer adults with a body mass	
		index (BMI) of 30 or higher	
		(calculated as weight in kilograms	
		divided by height in meters	
		squared) to intensive,	Little notable difference here. The pre-
		multicomponent behavioral	ACA says to offer interventions to obese
		interventions.	adults and the post-ACA version says
			individuals with a BMI of 30 or higher –
<u>November 3, 2003</u>	All Adults	Recommends clinicians screen all	which is the definition of obese.
	("B")	adult patients for obesity and offer	
		intensive counseling and behavioral	
		interventions to promote sustained	
		weight loss for obese adults.	
	Ohesity	in Children and Adolescents: Screer	nings <sup>18,19</sup>
June 20, 2017*	Children and	Recommends that clinicians screen	
Julie 20, 2017	adolescents 6 years	for obesity in children and	
	and older	adolescents 6 years and older and	
	una oraci	offer or refer them to	
		comprehensive, intensive	
		behavioral interventions to	
		promote improvements in weight	No change
		status.	
January 15, 2010	Children aged 6	Recommends that clinicians screen	
	years and older	children aged 6 years and older for	
		obesity and offer them or refer	

<sup>&</sup>lt;sup>17</sup> Excess body weight (including overweight or obesity) is associated with an increased risk of developing several types of cancer including uterine corpus (endometrium), esophagus (adenocarcinoma), liver, stomach (cardia), kidney (renal cell), meningioma, multiple myeloma, pancreas, colorectum, gallbladder, ovary, female breast (postmenopausal), and thyroid. American Cancer Society. *Cancer Prevention & Early Detection Facts & Figures 2021-2022*. Atlanta: American Cancer Society; 2021.

<sup>&</sup>lt;sup>18</sup> There were no intervening USPSTF recommendations between January 2010 and June 2017.

<sup>&</sup>lt;sup>19</sup> The USPSTF issued weight loss to prevent obesity-related morbidity and mortality recommendations in <u>June 2012</u>.

USPSTF			Key Difference Between	
Recommendation	Who is covered	What is covered	Recommendations	
		them to comprehensive, intensive behavioral intervention to promote improvement in weight status.		
Tol	bacco <sup>20</sup> Smoking Cess	ation in Adults, Including Pregnant	Persons: Interventions <sup>21</sup>	
January 19, 2021	Pregnant persons ("A")	Recommends clinicians ask all pregnant persons about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant persons who use tobacco.	Pregnant women: the pre-ACA recommendation did not include a	
	Nonpregnant adults ("A")	them to stop using tobacco, and provide behavioral interventions and FDA-approved pharmacotherapy for cessation to nonpregnant adults who use	recommendation to advise pregnant women to stop using tobacco (but to ask about tobacco use and recommend counseling). The 2021 recommendation recommends providers advise pregnant women to stop using tobacco.  Non-pregnant adults: the pre-ACA recommendation did not recommend	
April 15, 2009	Pregnant Women ("A")	use and provide augmented, pregnancy-tailored counseling for	that providers advise individuals to stopusing tobacco. The 2021 recommendation provides greater clarin tobacco cessation interventions (specifically including FDA-approved pharmacotherapy).	
	All Adults ("A")	Recommends clinicians ask all adults about tobacco use and provide tobacco cessation interventions for those who use tobacco products.		
Tobacco Use in Children and Adolescents: Primary Care Interventions <sup>22</sup>				
April 28, 2020	and adolescents who	including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.	NEW RECOMMENDATION:  The 2020 recommendation recommends primary care clinicians provide interventions, including education or brief counseling to prevent initiation of	
November 1, 2003	Children and adolescents	USPSTF concludes that the evidence is insufficient to	tobacco use. The pre-ACA recommendation did not.	

\_

<sup>&</sup>lt;sup>20</sup> In addition to lung cancer, cigarette smoking increases the risk of other cancers including those of the oral cavity and pharynx, larynx, esophagus, pancreas, uterine, cervix, kidney, bladder, stomach, colorectum, and liver. *Cancer Prevention & Early Detection Facts & Figures 2021-2022*.

<sup>&</sup>lt;sup>21</sup> The USPSTF issued tobacco cessation in adults intervention in <u>September 2015</u>.

<sup>&</sup>lt;sup>22</sup> The USPSTF issued tobacco use in children and adolescents: primary care intervention recommendations in <u>August 2013</u>.

Who is covered  Pecommendation  ("I")  Recommend for or against routine screening for tobacco use or interventions to prevent and treat tobacco use and dependence among children or adolescents.  Hepatitis B <sup>23</sup> Virus Infection in Adolescents and Adults: Screening <sup>24</sup> December 15, 2020  Adolescents and adults at increased risk for infection  ("B")  Adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  February 15, 2004  Adults  Recommends against routinely screening for adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  February 15, 2004  Hepatitis B Virus Infection in Pregnant Women: Screening <sup>25</sup>				
recommend for or against routine screening for tobacco use or interventions to prevent and treat tobacco use and dependence among children or adolescents.  Hepatitis B <sup>23</sup> Virus Infection in Adolescents and Adults: Screening <sup>24</sup> December 15, 2020 Adolescents and adults at increased risk for infection ("B")  Recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.				
Screening for tobacco use or interventions to prevent and treat tobacco use and dependence among children or adolescents.  Hepatitis B <sup>23</sup> Virus Infection in Adolescents and Adults: Screening <sup>24</sup> December 15, 2020 Adolescents and adults at increased risk for infection ("B")  Recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  February 15, 2004  Adults  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
interventions to prevent and treat tobacco use and dependence among children or adolescents.  Hepatitis B <sup>23</sup> Virus Infection in Adolescents and Adults: Screening <sup>24</sup> December 15, 2020  Adolescents and adults at increased risk for infection.  ("B")  Recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  February 15, 2004  Adults  Recommends section for a description of adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  February 15, 2004  Adults  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
tobacco use and dependence among children or adolescents.  Hepatitis B <sup>23</sup> Virus Infection in Adolescents and Adults: Screening <sup>24</sup> December 15, 2020 Adolescents and adults at increased risk for infection ("B")  Recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
Hepatitis B <sup>23</sup> Virus Infection in Adolescents and Adults: Screening <sup>24</sup> December 15, 2020 Adolescents and adults at increased risk for infection ("B")  Recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommendation is sued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.				
December 15, 2020 Adolescents and adults at increased risk for infection  ("B")  Recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommends against screening for adolescents and adults at increased risk for infection.  Recommendation is for screening for adolescents and adults at increased risk of infection.				
December 15, 2020 Adolescents and adults at increased risk for infection  ("B")  Recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommends against screening for adolescents and adults at increased risk for infection.  Recommendation is for screening for adolescents and adults at increased risk of infection.				
adults at increased risk for infection  ("B")  Adults  Adults  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population.  February 15, 2004  Adults  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection.  NEW RECOMMENDATION:  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.				
risk for infection  ("B")  adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  February 15, 2004  Adults  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
risk for infection  ("B")  adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.  February 15, 2004  Adults  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommendation issued prior to the enactment of the ACA recommended against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.				
Considerations section for a description of adolescents and adults at increased risk for infection.  February 15, 2004  Adults  ("D")  Considerations section for a description of adolescents and adults at increased risk for infection.  Endown and adults against screening general asymptomatic population. Current recommendation is for screening for adolescents and adults at increased risk of infection.  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
description of adolescents and adults at increased risk for infection.  February 15, 2004  Adults  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
adults at increased risk for infection.  February 15, 2004  Adults  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
adults at increased risk for infection.  February 15, 2004  Adults  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
February 15, 2004  ("D")  Infection.  February 15, 2004  ("D")  Infection.  February 15, 2004  ("D")  February 15, 2004  Adults  Screening the general asymptomatic population for chronic hepatitis B virus infection.				
February 15, 2004  Adults  Recommends against routinely screening the general asymptomatic population for chronic hepatitis B virus infection.				
("D")  screening the general asymptomatic population for chronic hepatitis B virus infection.				
asymptomatic population for chronic hepatitis B virus infection.				
chronic hepatitis B virus infection.				
Hepatitis B Virus Infection in Pregnant Women: Screening <sup>25</sup>				
Hepatitis B Virus Infection in Pregnant Women: Screening <sup>25</sup>				
Hepatitis B Virus Infection in Pregnant Women: Screening <sup>25</sup>				
July 23, 2019 Pregnant Women Recommends screening for				
hepatitis B virus (HBV) infection in				
("A") pregnant women at their first				
prenatal visit  No change				
February 15, 2004 Pregnant Women Strongly recommends screening for				
Hepatitis B Virus (HBV) infection in				
("A") pregnant women at their first				
prenatal visit.  Hepatitis C <sup>26</sup> Virus Infection in Adolescents and Adults: Screening <sup>27</sup>				
ricputitis C Virus infection in Adolescents and Addies. Scienting				
March 2, 2020 Adults aged 18 to 79 Recommends screening for				
years hepatitis C virus (HCV) infection in NEW RECOMMENDATION:				
adults aged 18 to 79 years.				

<sup>&</sup>lt;sup>23</sup> Chronic infection with hepatitis B virus (HBV) causes liver cancer and has been shown to increase the risk of non-Hodgkin lymphoma. *Cancer Prevention & Early Detection Facts & Figures 2021-2022*.

<sup>&</sup>lt;sup>24</sup> In <u>June 2014</u> the USPSTF issued a B recommendation for screening for Hep B virus infection in persons at high risk for infection.

<sup>&</sup>lt;sup>25</sup> The USPSTF issued Hepatitis B screening for pregnant women recommendations in <u>June 2009</u>.

<sup>&</sup>lt;sup>26</sup> Chronic infection with hepatitis C virus (HCV) causes liver cancer and has been shown to increase the risk of non-Hodgkin lymphoma. *Cancer Prevention & Early Detection Facts & Figures 2021-2022*.

<sup>&</sup>lt;sup>27</sup> The USPSTF issued a Hepatitis C screening recommendation in <u>June 2013</u>.

March 8, 2004	Who is covered  Adults who are not increased risk for infection  ("D")	The USPSTF recommends against	Key Difference Between Recommendations The 2020 recommendation recommends screening for adults 18-75. The pre-ACA recommendation did not.
	T	cents and Adults: Screening and Beh	navioral Counseling Interventions <sup>29</sup>
November 13, 2018	Adults 18 years or older, including pregnant women ("B")	Recommends screening for unhealthy alcohol use in primary care settings in adults 18 years or older, including pregnant women, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.	No real change, essentially the same recommendation pre & post ACA.
April 6, 2004	Adults, including pregnant women ("B")	Recommends screening and behavioral counseling interventions to reduce alcohol misuse by adults, including pregnant women, in primary care settings.	

<sup>&</sup>lt;sup>28</sup> Approximately 6% of cancer cases can be attributed to alcohol consumption, which increases the risk for cancers of the mouth, pharynx, larynx, esophagus, liver, colorectum, and female breast. Cancer Prevention & Early Detection Facts & Figures 2021-2022.